세계의 보조생식기술(ART) 시장 : 기술별, 유형별, 환자 유형별, 최종사용자별 - 예측(-2030년)

The assisted reproductive technology market is projected to reach USD 6.02 Billion by 2030 from USD 4.29 Billion in 2025 at a CAGR of 7.0% during the forecast period.

Increasing rates of infertility due to delayed conception, altered lifestyles, and growing awareness of fertility treatment are driving the assisted reproductive technology (ART) market. Further impetus to market growth is coming from improvements in medical technology, improved treatment success rates with in-vitro fertilization (IVF), and favorable government policies. But some of these limitations are the cost of treatment, ethical and legal issues, and health risks associated with ART procedures. Inadequacy of fertility treatment in developing nations and physical and psychological stress of ART also limit market growth. Research and development are, in spite of these limitations, enhancing the price and effectiveness of ART treatments.

"The IVF segment is accounted for the largest share of global assisted reproductive technology market."

IVF has become the ART procedure of choice over other treatments due to innovations like time-lapse imaging, embryo freezing, and preimplantation genetic testing (PGT), which have greatly enhanced IVF success. Global demand for IVF has also been driven by delayed pregnancy, rising infertility, and greater awareness of fertility treatment. IVF domination of the market is also driven by greater medical tourism practice, government subsidization of ART procedures, and greater numbers of fertility clinics.

Due to its high success rates, commonality of use, and ongoing technological advancements, the IVF category maintains the largest market share in the assisted reproductive technology (ART) market.

The best treatment for infertility, in vitro fertilization (IVF), can treat many different kinds of infertility problems, including unexplained infertility, male factor infertility, and older mother age.

"Fertility clinics has the largest market share in assisted reproductive technology market."

Fertility clinics enjoy the largest market share among the assisted reproductive technology market in care facilities owing to the growing demand for specialist reproductive treatments, high-technology healthcare facilities, and the increased number of infertile patients worldwide. Since ART therapies provided are heterogeneous in nature, encompassing intrauterine insemination, in-vitro fertilization, freezing eggs and sperm, and preimplantation genetic diagnosis, fertility clinics remain the preferred option for those who require fertility therapies. Expansion of private fertility clinics, government initiatives, and growing awareness regarding reproductive therapies have also driven the growth of this segment. Fertility clinics' dominance in the ART business is also complemented by the growing trend of medical tourism for affordable ART therapy in Thailand, India, and Spain.

"Asia Pacific holds the largest market share in the assisted reproductive technology market."

Asia-Pacific holds the maximum market share in the ART market due to its large population, large infertility rates, and strong awareness of fertility treatment. There is growing demand for ART treatment in the region at a rapid rate due to factors such as delayed parenthood, changing lifestyles, and high levels of stress that exacerbate fertility. Government-sponsored programs for ART funding, the proliferation of fertility clinics, and advances in reproductive technology have all contributed to the growth in the market. Key drivers are countries such as China, India, and Japan, which offer low-cost fertility treatments that are in great demand among medical tourists. Asia-Pacific's market dominance is also supported by increasing acceptance of ART as well as the increase in the affordability of healthcare and infrastructure.

A breakdown of the primary participants (supply-side) for the assisted reproductive technology market referred to for this report is provided below:

• By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3-30%
• By Designation: C-level-55%, Director Level-27%, and Others-18%
• By Region: North America-35%, Europe-32%, Asia Pacific-25%, Latin America- 5%, and Middle East and Africa- 1% and GCC Countries- 2%

Prominent players in this market include CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), Thermo Fisher Scientific Inc. (US), LENUS Pharma GesmbH (Austria), Zita West (UK), Kitazato Corporation (Japan), Exeltis USA, Inc. (US), Vitabiotics Ltd (UK), FertiPro NV (Belgium), and AdvaCare Pharma (US), among others.

Research Coverage:

The market study covers the assisted reproductive technology market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by type, technology, patient type, care setting and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of Market Dynamics: Drivers (Increasing median age of pregnancy, Rising infertility rate, Booming fertility industry, Evolving technological landscape, Favorable government initiatives) restraints (High cost of IVF procedures, Social and ethical concerns in developing countries, Elevated risk of complications) opportunities (Growth opportunities in emerging economies, Availability of diverse range of fertility treatment options), and challenges (Reduced efficacy of infertility treatments among patients of advanced age)
• Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the assisted reproductive technology market.
• Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, care settings, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the assisted reproductive technology market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the assisted reproductive technology market like CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), and Thermo Fisher Scientific Inc. (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH DESIGN
  • 2.2.1 SECONDARY RESEARCH
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY RESEARCH
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key industry insights
    • 2.2.2.3 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 SUPPLY-SIDE ANALYSIS
  • 2.3.2 BOTTOM-UP APPROACH
    • 2.3.2.1 Company revenue estimation approach
    • 2.3.2.2 Customer-based market estimation
    • 2.3.2.3 Demand-side market size estimation
    • 2.3.2.4 Growth forecast approach
• 2.4 DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET OVERVIEW
• 4.2 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE AND COUNTRY
• 4.3 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: REGIONAL MIX
• 4.5 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing median age of pregnancy
    • 5.2.1.2 Rising infertility rate
    • 5.2.1.3 Booming fertility industry
    • 5.2.1.4 Evolving technological landscape
    • 5.2.1.5 Favorable government initiatives
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of IVF procedures
    • 5.2.2.2 Social and ethical concerns in developing countries
    • 5.2.2.3 Elevated risk of complications
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging economies
    • 5.2.3.2 Availability of diverse range of fertility treatment options
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Reduced efficacy of infertility treatments for patients of advanced age
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
  • 5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
  • 5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
• 5.6 SUPPLY CHAIN ANALYSIS
  • 5.6.1 PROMINENT COMPANIES
  • 5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES
  • 5.6.3 END USERS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Time-lapse technology
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Preimplantation genetic testing
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Sperm cryopreservation
    • 5.9.3.2 Oocyte cryopreservation
• 5.10 PATENT ANALYSIS
• 5.11 TRADE DATA ANALYSIS
  • 5.11.1 IMPORT DATA
  • 5.11.2 EXPORT DATA
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 CASE STUDY 1: ENHANCED IVF RATES USING EMBRYOTOXICITY, PLATELET LEUKOCYTE AGGREGATES, AND NATURAL KILLER DIAGNOSIS
  • 5.13.2 CASE STUDY 2: IMPROVED EMBRYO SELECTION THROUGH AI-DRIVEN PLATFORM
  • 5.13.3 CASE STUDY 3: ASSESSMENT OF EMBRYO VIABILITY USING AI-DRIVEN SYSTEMS
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14.2 REGULATORY FRAMEWORK
    • 5.14.2.1 North America
      • 5.14.2.1.1 US
      • 5.14.2.1.2 Canada
    • 5.14.2.2 Europe
    • 5.14.2.3 Asia Pacific
      • 5.14.2.3.1 India
      • 5.14.2.3.2 Japan
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 THREAT OF NEW ENTRANTS
  • 5.15.2 THREAT OF SUBSTITUTES
  • 5.15.3 BARGAINING POWER OF BUYERS
  • 5.15.4 BARGAINING POWER OF SUPPLIERS
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 UNMET NEEDS
• 5.18 REIMBURSEMENT SCENARIO
• 5.19 IMPACT OF AI/GEN AI ON ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 MARKET POTENTIAL OF AI IN ASSISTED REPRODUCTIVE TECHNOLOGY
  • 5.19.3 AI USE CASES
  • 5.19.4 KEY COMPANIES IMPLEMENTING AI
  • 5.19.5 FUTURE OF GENERATIVE AI IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET

6 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 IN VITRO FERTILIZATION
  • 6.2.1 IVF WITH ICSI
    • 6.2.1.1 Higher success rates than conventional methods to stimulate growth
  • 6.2.2 IVF WITHOUT ICSI
    • 6.2.2.1 Preferred choice for less severe infertility issues to facilitate growth
• 6.3 ARTIFICIAL INSEMINATION
  • 6.3.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE TREATMENTS TO DRIVE MARKET

7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE

• 7.1 INTRODUCTION
• 7.2 INSTRUMENTS
  • 7.2.1 EMBRYO INCUBATORS
    • 7.2.1.1 Need for undisturbed and protective environment throughout incubation to aid growth
  • 7.2.2 SPERM ANALYZER SYSTEMS
    • 7.2.2.1 Capability to identify fertility problems and determine appropriate interventions to fuel market
  • 7.2.3 MICROMANIPULATORS
    • 7.2.3.1 Increased adoption of micromanipulators in intracytoplasmic sperm injections and embryo biopsies to boost market
  • 7.2.4 OTHER INSTRUMENTS
• 7.3 MEDIA
  • 7.3.1 EMBRYO CULTURE MEDIA
    • 7.3.1.1 Close resemblance to natural environment to amplify growth
  • 7.3.2 CRYOPRESERVATION MEDIA
    • 7.3.2.1 Ability to protect cells from damage to drive market
  • 7.3.3 SEMEN PROCESSING MEDIA
    • 7.3.3.1 Growing application in washing, capacitation, and sperm selection to boost market
  • 7.3.4 OVUM PROCESSING MEDIA
    • 7.3.4.1 Ability to mimic natural conditions of female reproductive tract to aid growth
• 7.4 SUPPLEMENTS
  • 7.4.1 RISING DEMAND FOR FERTILITY-ENHANCING SUPPLEMENTS TO SUPPORT GROWTH
• 7.5 CONSUMABLES
  • 7.5.1 CULTURE DISHES & PLATES
    • 7.5.1.1 Growing advancements in embryo incubation to drive market
  • 7.5.2 STORAGE CONTAINERS
    • 7.5.2.1 Increasing use of cryopreservation techniques to expedite growth
  • 7.5.3 CRYOVIALS & TUBES
    • 7.5.3.1 Growing trend of egg and embryo freezing for delayed parenthood to boost market
  • 7.5.4 OTHER CONSUMABLES

8 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE

• 8.1 INTRODUCTION
• 8.2 FEMALE PATIENTS
  • 8.2.1 RISING FEMALE INFERTILITY RATE TO AMPLIFY GROWTH
• 8.3 MALE PATIENTS
  • 8.3.1 LIFESTYLE CHANGES AND INCREASING INCIDENCE OF LOW SPERM COUNT TO PROMOTE GROWTH

9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 FERTILITY CLINICS
  • 9.2.1 INCREASED AVAILABILITY AND ACCESSIBILITY OF FERTILITY CLINICS TO SUSTAIN GROWTH
• 9.3 HOSPITALS & SURGERY CLINICS
  • 9.3.1 NEED FOR ADVANCED LABORATORIES FOR GAMETE HANDLING AND ULTRASOUND MONITORING TO AID GROWTH
• 9.4 RESEARCH INSTITUTES
  • 9.4.1 ONGOING RESEARCH FOR COST-EFFECTIVE AND ADVANCED TECHNIQUES TO STIMULATE GROWTH
• 9.5 CRYOBANKS
  • 9.5.1 GROWING INCLINATION TOWARD FLEXIBLE TREATMENT TO FUEL MARKET

10 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Favorable infrastructure network to encourage growth
  • 10.2.3 CANADA
    • 10.2.3.1 Growing assistance from banks for fertility treatments to fuel market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Robust healthcare infrastructure to support growth
  • 10.3.3 UK
    • 10.3.3.1 Increasing focus on high-quality care at licensed fertility clinics to propel market
  • 10.3.4 FRANCE
    • 10.3.4.1 Growing healthcare expenditure to boost market
  • 10.3.5 ITALY
    • 10.3.5.1 Favorable regulatory guidelines to support market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Booming medical tourism to drive market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Increasing medical benefits for childbirth to intensify growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Low fertility rates to amplify growth
  • 10.4.4 INDIA
    • 10.4.4.1 Affordable treatment options to favor growth
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Declining fertility rate to advance growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Growing focus on reversing low population trend to drive market
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Rise in aging mothers to contribute to growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Growing network of state-of-the-art facilities to boost market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 RISING HEALTHCARE SPENDING TO FOSTER GROWTH
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 10.7 GCC COUNTRIES
  • 10.7.1 IMPROVED HEALTH INFRASTRUCTURE AND BETTER AWARENESS ABOUT FERTILITY TREATMENTS TO PROPEL MARKET
  • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.5.1 COMPANY VALUATION
  • 11.5.2 FINANCIAL METRICS
• 11.6 BRAND/PRODUCT COMPARISON
• 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.7.1 STARS
  • 11.7.2 EMERGING LEADERS
  • 11.7.3 PERVASIVE PLAYERS
  • 11.7.4 PARTICIPANTS
  • 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.7.5.1 Company footprint
    • 11.7.5.2 Region footprint
    • 11.7.5.3 Type footprint
    • 11.7.5.4 Product type footprint
    • 11.7.5.5 Patient type footprint
    • 11.7.5.6 End-user footprint
• 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.8.1 PROGRESSIVE COMPANIES
  • 11.8.2 RESPONSIVE COMPANIES
  • 11.8.3 DYNAMIC COMPANIES
  • 11.8.4 STARTING BLOCKS
  • 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.8.5.1 Detailed list of key startups/SMEs
    • 11.8.5.2 Competitive benchmarking of key startups/SMEs
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES
  • 11.9.2 DEALS
  • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 COOPERSURGICAL INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 FUJIFILM IRVINE SCIENTIFIC
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
      • 12.1.2.3.2 Other developments
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses
  • 12.1.3 VITROLIFE
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 THERMO FISHER SCIENTIFIC INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 MnM view
      • 12.1.4.3.1 Key strengths
      • 12.1.4.3.2 Strategic choices
      • 12.1.4.3.3 Weaknesses and competitive threats
  • 12.1.5 COOK MEDICAL INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 HAMILTON THORNE
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Deals
    • 12.1.6.4 MnM view
      • 12.1.6.4.1 Key strengths
      • 12.1.6.4.2 Strategic choices
      • 12.1.6.4.3 Weaknesses and competitive threats
  • 12.1.7 KITAZATO CORPORATION
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 ESCO MICRO PTE. LTD.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
  • 12.1.9 FERTIPRO NV
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 GENEA BIOMEDX
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Deals
  • 12.1.11 LENUS PHARMA GESMBH
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Product launches
  • 12.1.12 ZITA WEST
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 EXELTIS USA, INC.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 VITABIOTICS LTD.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 ADVACARE PHARMA
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
• 12.2 OTHER COMPANIES
  • 12.2.1 FAIRHAVEN HEALTH
  • 12.2.2 SHANGHAI UNICORN MEDICAL TECHNOLOGY CO., LTD.
  • 12.2.3 GYNEMED GMBH & CO. KG
  • 12.2.4 INVITROCARE INC.
  • 12.2.5 IVFTECH
  • 12.2.6 LABIVF ASIA PTE LTD.
  • 12.2.7 COAST SCIENCE
  • 12.2.8 BIOIMAGER INC.
  • 12.2.9 SHIVANI SCIENTIFIC
  • 12.2.10 MINITUB GMBH

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS